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Background
Therapy-related myeloid neoplasm (t-MN) is a distinct class of acute myeloid leukemia 
(AML) in the World Health Organization (WHO) classification. Both AML and acute lym-
phoblastic leukemia (ALL) may develop after treatment for primary cancer. Topoisomerase 
inhibitors are commonly used to treat breast cancer patients and are well-known for their 
effect on leukemogenesis of therapy-related acute leukemias (t-AL).
Methods
We retrospectively evaluated bone marrow test results, chromosomal findings, and clin-
ical characteristics of 12 patients who received topoisomerase inhibitors for breast cancer 
treatment and later developed acute leukemia.  
Results
Fourteen patients (0.2%) developed t-AL after treatment for breast cancer. Topoisomerase 
inhibitors were administered to 12 patients. Among them, 9 patients (75%, 9/12) were 
diagnosed with therapy-related AML (t-AML) and 3 patients (25%, 3/12) with therapy-re-
lated ALL (t-ALL). Eight patients (67%, 8/12) showed translocation involving 11q23 and 
3 different partner genes, 19p13.1 (37.5%, 3/8), 9p22 (37.5%, 3/8), and 4q21 (25%, 2/8). 
The median interval between completion of chemotherapy for breast cancer and occur-
rence of t-AL was 25 months. Patients with 11q23 translocation showed markedly poorer 
event-free survival than the group without involvement of 11q23.  
Conclusion
The incidence rate of t-AL after treatment for breast cancer was 0.2% in a tertiary hospital 
in Korea. Translocation involving the MLL gene was frequently found in t-AL caused by 
a topoisomerase inhibitor and was related to poor prognosis. 
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INTRODUCTION
  Therapy-related acute leukemia (t-AL) is the most severe 
complication that may occur after treatment for primary 
cancer. It is diagnosed on the basis of histories of treatment 
and molecular abnormalities, and develops after chemo-
therapy, radiation, or immunosuppressive agents performed 
for the management of the primary cancer [1]. The World 
Health Organization (WHO) recognizes therapy-related 
myeloid neoplasm (t-MN) as a distinct subtype of acute mye-
loid leukemia (AML), although acute lymphoblastic leukemia 
(ALL) may also arise [2]. Topoisomerase inhibitors and alky-
lating agents are 2 well-known antineoplastic agents that 
cause t-AL [3]. 
  The incidence rate of t-AL among patients treated for 
breast cancer has been reported to be 0.2-0.5% [4]. Breast 
cancer is the second most common cancer in Korean women, 
and such serious side effects are a matter of concern [5]. 
Topoisomerase inhibitors are part of cocktail treatment regi-
mens for breast cancer patients. Topoisomerase inhibitors 
act as antineoplastic agents by binding to the DNA/enzyme Korean J Hematol 2010;45:177-82.
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complex inhibiting the action of topoisomerase, thus leaving 
behind a single strand of DNA. Multiple DNA-strand breaks 
lead to cell death but these breaks, which are repaired by 
chromosomal translocation, initiate leukemogenesis [1]. 
  t-AL constitutes 10-20% of all cases of AL [1]. However, 
only sporadic cases of t-AL after systemic chemotherapy 
have been reported in Korea [6]. Although many epidemio-
logic studies have been conducted in other countries, no 
such literature exists on t-AL in the Korean population. 
Herein, we report the clinical characteristics, chromosomal 
findings, and bone marrow test results of 12 cases of t-AL 
that developed after topoisomerase inhibitor therapy in 
breast cancer patients in a single institute.
MATERIALS AND METHODS
1. Case selection
  We reviewed the electronic medical records of patients 
who were primarily diagnosed with breast cancer and later 
developed AL and underwent treatment at the Asan Medical 
Center, Seoul, Korea, from 1989 to October 2009. A total 
of 9,228 patients were diagnosed and treated for breast 
cancer. Among them, 14 patients (0.2%) later developed 
t-AL. Two patients were excluded from this study: the ther-
apeutic regimen of 1 patient did not include topoisomerase 
inhibitors and the other patient had been treated at a different 
hospital, and her medication history could not be evaluated. 
We retrospectively evaluated the medication record, history 
of radiation treatment, bone marrow test results, im-
munophenotypic results, and cytogenetic results of the in-
cluded patients. 
2. Morphologic examination and immunophenotypic analysis
  Peripheral blood and bone marrow aspirates were prepared 
with Wright-Giemsa staining for morphologic evaluation. 
Conventional panels were chosen for the analysis of AML 
and ALL markers and the FACSCanto flow cytometer 
(BectonDickinson, San Jose, CA, USA) was used.
3. Cytogenetic analysis
  Cytogenetic analysis was performed on bone marrow spe-
cimens using standard techniques. Giemsa-trypsin-Giemsa 
(GTG) banding was used to identify the chromosome. At 
least 20 metaphase cells were examined after 24-hr culture. 
The chromosomes were evaluated under 300-400 bands reso-
lution according to the International System for Human 
Cytogenetic Nomenclature (2009) [7].
4. Statistical analysis for event-free survival
  Event-free survival of 12 patients was analyzed. We div-
ided the cases into the 11q23 rearranged group and non- 
11q23-involved group. The Wilcoxon test was used to plot 
the survival graph of the 2 groups.
RESULTS
1. Clinical features of the cases 
  Doxorubicin (Admycin; BoRyung Pharm, Seoul, Korea), 
which inhibits the progression of topoisomerase, was used 
in 12 patients. Alkylating agents were used together with 
doxorubicin in 10 patients. The participants were all female 
patients with a median age of 55 years. The period between 
completion of chemotherapy for breast cancer and diagnosis 
of t-AL was 18-95 months with a median period of 25 months. 
The patients’ event-free survival after diagnosis of AL was 
1-39 months. Five patients died, 3 patients are still alive, 
and 4 patients were lost to follow-up (Table 1). 
2. Hematologic features of the cases 
  Nine patients were diagnosed with therapy-related AML 
(t-AML) (75%, 9/12) and 3 patients (25%, 3/12) with ther-
apy-related ALL (t-ALL). At the time of diagnosis, the average 
white blood cell count was 13,066/μL; median platelet count, 
33,000/μL; median hemoglobin level, 7.6 g/dL; median per-
centage of blasts in the blood, 21%; and median percentage 
of blasts in the bone marrow aspirates, 79.2%. Leukemic 
blasts showed a “packed marrow” pattern with cellularity 
ranging from 75 to 100%.
  One patient with mixed-lineage AML (case No. 7) showed 
2 distinct populations of blasts (Fig. 1A) in the marrow 
aspirates. Also, her bone marrow biopsy revealed extensive 
myelofibrosis involving many myeloblasts and lymphoblasts 
(Fig. 1B). In another patient (case No. 3) diagnosed with 
t-MN, the percentage of blasts in the bone marrow aspirate 
was only 11.2%, and her bone marrow biopsy showed 
“packed marrow” infiltration of myeloid cells with variable 
maturation stages and scattered myeloblasts (Fig. 2) 
3. Cytogenetic features of the cases 
  Eight patients (67%, 8/12) had translocation of 11q23 
(MLL), of which 3 patients showed translocation of 19p13.1 
(ELL) (37.5%, 3/8), 3 patients of 9p22 (AF9) (37.5%, 3/8), 
and 2 patients of 4q21 (AF4) (25%, 2/8). The karyotypes 
of the remaining 4 patients were 2 normal karyotypes, 1 
t(15;17), and 1 with -9/-13. Among the 8 cases of 11q23 
rearrangement, 7 cases were diagnosed as t-AML and only 
1 case was diagnosed as t-ALL.
4. Survival analysis and period between completion of treat-
ment for breast cancer and diagnosis of t-AL; 11q23 vs. 
non-11q23 
  We analyzed the event-free survival of 12 patients. We 
divided the cases into 2 groups, the 11q23-rearranged group 
and the non-11q23-involved group. The Wilcoxon test was 
used to plot the survival graph of the 2 groups; the graph 
showed that the 11q23 group had significantly poorer surviv-
al (P=0.043) (Fig. 3). The mean period between completion 
of treatment for breast cancer and t-AL was 32.4 months 
in the 11q23 group and 43.3 months in the non-11q23 group 
(P=0.234).Korean J Hematol 2010;45:177-82.
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Fig. 1. Mixed lineage AML (Case No. 7). (A) Bone marrow aspirate (Wright-Giemsa, ×1,000), showing 2 distinct populations of blasts. (B) Bone 
marrow biopsy (H&E, ×400), with heavily infiltrated blasts with extensive myelofibrosis.
Table 1. Demographics and laboratory findings of 12 patients.
Case 
no.
Age
ChemoRx 
regimens
RTx
Type 
AML/ALL
Interval
(mo)
Karyotype
Translo-
cated 
genes
Survival 
(mo)
WBC
(cells/μL)-Hb
(g/dL)-Plt
(k/μL)
PB/BM 
Blasts
(%)
Immuno-
phenotype 
positivity
15 5 AC+F + AML M5a 24 46,XX,t(9;11)(p22;q23)
[19]/46,XX[2]
MLL-AF9 23 13,600-8.4-48 12-81.4 CD13, CD33,
HLA-DR, CD7
24 1 A+CIS+TAC + AML M4 84 46,XX,t(9;11)(p22;q23)[20] MLL-AF9 1 28,000-8.5-30 3-79.2 Not done 
35 8 AC _ AML NOS 31 46,XX,+9,t(9;11)(p22;q23)
[17]/46,XX[3]
MLL-AF9 15 16,600-10.5-20 14-11.2 CD13, CD33, 
CD15, CD65
45 4 AC _ AML M4 24 46,XX,t(11;19)(q23;p13.1)
[19]/46,XX[1]
MLL-ELL 3 102,400-7.5-38 45-49.8 CD13, CD33, 
CD117
54 3 AC+ AML M2 25 46,XX,t(11;19)
(q23;p13.1)[20]
MLL-ELL 3 18,600-10.2-68 21-33.2 CD13, CD33
65 9 AC _ AML M0 22 47,XX,+X,t(11;19)
(q23;p13.1)[15]/46,XX[5]
MLL-ELL 10 1,700-8.0-30 5-84.2 CD33, CD15, CD65,
CD34, TdT, CD19
76 2 AC _ AML Mixed 31 46,XX,t(4;11)(q21;q23)
[8]/46,X,del(X)(q24),
t(4;l1)(q21;q23)[2]/
46,XX[10]
MLL-AF4 3 2,560-7.6-51 4-73.2 CD13, CD15,
CD34, CD19, TdT
85 6 AC+F + AML M3 95 46,XX,t(15;17)
(q22;q12)[20]
PML-RARA 30 39,200-7.3-33 89-83.4 Not done 
95 3 AC+TAC + AML M2 21 46,XX[20] 36 2,500-4.5-7 32-50.2 CD13, CD33, CD117,
CD41, CD19, CD7
10 68 AC+ ALL L1 18 47,XX,t(4;11)(q21;q23),
+8[8]/48,idem,+21[9]/49,
idem,+der(4)t(4;11),
+21[2]/49,idem,+8,+21[1]
MLL-AF4 27 3,600-7.1-42 27-96.4 CD19, TdT, 
HLA-DR
11 56 A+VCS + ALL L2 32 46,XX[20] 11 4,200-8.5-74 76–92.4 CD19, CD20, 
CD38, HLA-DR, 
TdT, CD3, CD7
12 52 AC+ ALL L1 25 44,XX,-9,-13[16]/46,XX[4] 39 1,800-7.1-23 25-97.8 CD10, CD19, 
CD20, HLA-DR
Abbreviations: A, Admycin (doxorubicin hydrochloride); C, Alkyloxan (cyclophosphamide); F, 5FU (fluorouracil); CIS, Cisplatin; TAC, Taxol 
(paclitaxel); VCS, vincristine sulfate; RTx, radiation treatment; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; TdT, terminal
deoxynucleotidyl transferase; HLA, human leukocyte antigen.Korean J Hematol 2010;45:177-82.
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Fig. 2. Therapy-related myeloid neoplasm (Case No. 3). (A) Bone marrow biopsy (H&E, ×400), (B) (H&E, ×1,000), showing “packed marrow”
infiltration of myeloid cells of different maturation stages, and scattered myeloblasts.
Fig. 3. Event-free survival plot of 11q23 group vs. non-11q23 group, 
showing significantly poorer survival of the 11q23 translocated group 
(P=0.043).
DISCUSSION
  In this study, we selected cases with a history of treatment 
with a topoisomerase inhibitor prior to the onset of acute 
leukemia. Among the 12 patients treated with a topoiso-
merase inhibitor, 8 patients (67%) displayed a balanced trans-
location of the MLL gene located in the 11q23 chromosomal 
region. A balanced translocation involving 11q23 is charac-
teristic of topoisomerase inhibitor-induced t-AL [8]. One 
patient who was excluded from this study because we did 
not have her medication record showed t(3;3), suggesting 
a lower likelihood of topoisomerase inhibitor usage. Except 
for 1 patient, the latency period between completion of che-
motherapy and diagnosis of t-AL ranged from 18-32 months 
in 11q23-involved cases, which agreed with the established 
period of 1-3 years. In the patient with PML-RARA re-
arrangement (case No. 8), t-AL was diagnosed 95 months 
after completion of chemotherapy which was relatively long 
compared to the cases with MLL gene rearrangement. The 
latency period between completion of chemotherapy and 
diagnosis of t-AL for cases with PML-RARA rearrangement 
has not been reported but it is not thought to be longer 
than that of cases with MLL rearrangement. Although the 
latency periods are established in general, it can vary in-
dividually depending on many risk factors. 
  The survival analysis of our cases showed that t-AL with 
11q23 rearrangement presented poor prognosis. t-AL cases 
with 11q23 rearrangements are known for poor prognosis 
and 1 study showed that only 80% of patients achieved 
remission and 75% of them relapsed within 1 year [9]. Chen 
et al. reviewed t-ALL cases reported in the literature and 
concluded that the prognosis of t-ALL was much poorer 
compared to t-AML [10]. They also noted that survival did 
not differ between the 11q23 group and non-11q23 group 
in t-ALL patients. The overall prognosis in t-ALL was poor, 
regardless of the presence or absence of 11q23 abnormalities. 
Although our cases are limited in number, 1 patient with 
11q23-involved t-ALL (case No. 10) had a relatively long 
event-free survival (27 months) compared to the other 2 
t-ALL patients. 
  The MLL protein transcribed by the MLL gene is a critical 
transcriptional regulator and is essential for the maintenance 
of adult hematopoietic stem cells and progenitors. A key 
feature of MLL fusion proteins is their ability to efficiently 
transform hematopoietic cells into leukemic stem cells [11]. 
Over 40 different partner genes for 11q23 have been reported, 
with 9p22, 19p13.1, and 4q21 being the most well-known 
[12]. The results of our cases agree with the previously re-
ported data. Up to 30% of t(11;19)(q23;p13.1), 10% of t(9;11), Korean J Hematol 2010;45:177-82.
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and 5% of t(4;11) were found in patients with secondary 
leukemia. The gene located in the 9p22 chromosomal region 
is MLLT3, myeloid/lymphoid or mixed lineage leukemia 
translocated to 3, also known as AF9 (ALLL1-fused gene 
from chromosome 9), is responsible for proteins that act 
as transcription activator and is a frequent partner gene 
in  MLL rearrangements. In de novo cases, the prognosis 
of t(9;11)(p22;q23) leukemia may not be as poor as in other 
11q23 leukemia, but a very poor prognosis may be expected 
in patients with t-AL [13]. The 19p13.1 chromosomal region 
bears the ELL (eleven-nineteen lysine-rich leukemia) gene 
that transcribes proteins that function as RNA polymerase 
II elongation factor. t(11;19)(q23;p13.1) is related to very 
poor prognosis. A hybrid, mutated gene of 5'MLL-3'ELL 
produces abnormal proteins similar to other MLL fusion 
proteins and plays a role in oncogenesis [14]. AF4-MLL trans-
location, t(4;11)(q21;q23), is also known to be related to 
poor prognosis [15]. 
  Our study revealed that the incidence of t-AL among 
patients treated for breast cancer was 0.2%. A German study 
reported a rate of 0.2-0.5% of t-AL among breast cancer 
patients [16]. Such incidence rate suggests that there might 
be specific predisposing factors for t-AL. Host-associated fac-
tors have been hypothesized, including heritable predis-
position due to enzymatic polymorphisms in genes involved 
in DNA repair or drug metabolism [17, 18]. Polymorphisms 
in the gene of phase I enzymes, mainly the CYP family 
and phase II enzymes, are associated with decreased enzy-
matic activity in t-AL. Reduced activity of these enzymes 
and reduced detoxification result in increased production 
of activated metabolites and increased toxicity of chemo-
therapy [19]. Another mechanism of secondary leukemo-
genesis is DNA repair defects. Its susceptibility may be based 
on polymorphisms of DNA repair and synthesis, leading 
to incomplete repair and persistence of mutations [18].  
  Other than hereditary predispositions, Martin et al. sug-
gested that younger age and advanced stage of breast cancer 
predispose t-AML because these patients require higher doses 
of chemotherapeutic agents leading to t-AML [20]. In addi-
tion, they speculated on the possibility that early-onset breast 
cancer may have a genetic predisposition to t-AL and ques-
tioned the role mutations in the BRCA1 and 2 genes might 
play in the development of t-AL. The hypothesis could not 
be applied in our study because the participants were mid-
dle-aged women. Praga et al. reviewed 9,796 breast cancer 
patients and reported that the cumulative probability of de-
veloping AML/myelodysplastic syndrome (MDS) was 0.37% 
in patients treated with standard regimens, whereas the prob-
ability increased to 4.97% in those treated with higher doses 
of topoisomerase inhibitors. The dosage of chemotherapeutic 
agents had a significant effect on the development of t-AL 
[21].
  Several studies showed that combined radiotherapy and 
chemotherapy increased the risk of t-AL [22], whereas some 
suggested that limited-field radiation in the therapeutic dose 
range has very little or no effect on the risk of t-AL [1]. 
In our study, 8 patients had received radiation therapy and 
we did not observe a statistically significant effect on survival 
or latency period between completion of chemotherapy and 
diagnosis of t-AL.
  t-AML represents 10-20% of all AML cases [23], whereas 
t-ALL accounts for 2.3% of all ALL cases [24]. t-ALL accounts 
for a much lower proportion of cases of secondary leukemia 
than t-AML. The incidence of t-AML (75%) was higher 
than that of t-ALL (25%) in our study. The WHO distin-
guishes t-MNs as a distinct category, although ALL may 
also arise secondary to cancer therapy. Some groups reported 
that t(4;11) is associated with t-ALL, whereas t(9;11) is gen-
erally found in t-AML [25]. One case (case No. 10) with 
t-ALL with 11q23 abnormality showed t(4;11) which is in 
agreement with the report. A review of the literature revealed 
that 11q23 aberration was not observed in nearly one third 
of reported cases of t-ALL treated with topoisomerase in-
hibitors [10]. This finding indicates that mechanisms other 
than 11q23 aberration may also contribute to the t-ALL 
induced by topoisomerase inhibitors. 
  In our study, 10 patients were treated with both a top-
oisomerase inhibitor and an alkylating agent. However, most 
cases presented with either 11q23 aberration or a short la-
tency period between completion of chemotherapy and diag-
nosis of t-AL, i.e., patients with t-AL induced by a top-
oisomerase inhibitor. t-AL induced by alkylating agents gen-
erally presents with a longer latency period (5-7 years), pre-
ceding myelodysplastic features and frequent deletion of 
chromosomes 5, 5q, and/or 7, 7q [3]. The reason for the 
larger effect of topoisomerase inhibitors compared to alkylat-
ing agents remains unclear. Other factors such as dosage 
of each neoplastic agent might have had an effect. 
  Our presentation of 12 cases showed various features of 
t-AL after treatment with a topoisomerase inhibitor. We 
also observed that various types of AML were diagnosed 
other than myelomonocytic leukemia which is known to 
be the most prevalent type in AML associated with MLL 
gene rearrangement. t-AL patients with MLL gene rearrange-
ment had a significantly poorer prognosis. t-AL, which is 
a serious complication of cancer treatment, should receive 
more attention, especially since the incidence of breast cancer 
is increasing in the Korean population. In addition, further 
studies are required to identify and establish risk factors 
other than the hypothesized predisposing factors of t-AL.  
REFERENCES
1. Leone G, Fianchi L, Pagano L, Voso MT. Incidence and suscepti-
bility to therapy-related myeloid neoplasms. Chem Biol Interact 
2010;184:39-45.
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the 
World Health Organization (WHO) classification of myeloid ne-
oplasms and acute leukemia: rationale and important changes. 
Blood 2009;114:937-51. 
3. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related 
leukemia and myelodysplasia: susceptibility and incidence. Hae-
matologica 2007;92:1389-98. Korean J Hematol 2010;45:177-82.
182 Hyoeun Shim, et al. 
4. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leuke-
mia and myelodysplastic syndrome after doxorubicin-cyclo-
phosphamide adjuvant therapy for operable breast cancer: the 
National Surgical Adjuvant Breast and Bowel Project Experience. 
J Clin Oncol 2003;21:1195-204. 
5. Statistics of cancer reported by national cancer information 
center. Seoul, Korea: national cancer information center, 2006- 
2007. (Accessed July 21, 2010, at http://www.cancer.go.kr/cms/
statics/incidence/index.html.)
6. Cho J, Hur M, Moon HW, Yun YM, Lee CH, Lee HG. A case of 
therapy-related ALL with MLL gene rearrangement following 
treatment of breast cancer. Korean J Lab Med 2010;30:255-9. 
7. Shaffer LG, ed. An International System for Human Cytogenetic 
Nomenclature. Basel, Switzerland: ISCN, 2009. 
8. Harper DP, Aplan PD. Chromosomal rearrangements leading to 
MLL gene fusions: clinical and biological aspects. Cancer Res 
2008;68:10024-7. 
9. 11q23 rearrangements in therapy related leukaemias. Poitiers, 
France: Atlas Genet Cytogenet Oncol Haematol, 1998. (Accessed 
July, 20, 2010, at http://AtlasGeneticsOncology.org/Anomalies/ 
11q23secondLeukID1131.html.)
10. Chen W, Wang E, Lu Y, Gaal KK, Huang Q. Therapy-related acute 
lymphoblastic leukemia without 11q23 abnormality: report of six 
cases and a literature review. Am J Clin Pathol 2010;133:75-82. 
11. Krivtsov AV, Armstrong SA. MLL translocations, histone mod-
ifications and leukaemia stem-cell development. Nat Rev Cancer 
2007;7:823-33. 
12. MLL (myeloid/lymphoid or mixed lineage leukemia). Poitiers, 
France: Atlas Genet Cytogenet Oncol Haematol, 2005. (Accessed 
July 20, 2010, at http://AtlasGeneticsOncology.org/Genes/MLL. 
html.) 
13. MLLT3 (myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 3). Poitiers, France: Atlas 
Genet Cytogenet Oncol Haematol, 1997. (Accessed July 20, 2010, 
at http://AtlasGeneticsOncology.org/Genes/AF9.html.) 
14. ELL (eleven nineteen lysin rich leukemia gene). Poitiers, France: 
Atlas Genet Cytogenet Oncol Haematol, 2003. (Accessed July 20, 
2010, at http://AtlasGeneticsOncology.org/Genes/ELL.html.) 
15. AFF1 (AF4/FMR2 family, member 1). Poitiers, France: Atlas 
Genet Cytogenet Oncol Haematol, 2002. (Accessed July 20, 2010, 
at http://AtlasGeneticsOncology.org/Genes/AF4.html.) 
16. Dührsen U. Therapy-induced leukemia - an underestimated com-
plication of antineoplastic chemotherapy? Zentralbl Gynakol 
2005;127:235-41. 
17. Seedhouse C, Russell N. Advances in the understanding of sus-
ceptibility to treatment-related acute myeloid leukaemia. Br J 
Haematol 2007;137:513-29. 
18. Guillem V, Tormo M. Influence of DNA damage and repair upon 
the risk of treatment related leukemia. Leuk Lymphoma 2008; 
49:204-17. 
19. Bolufer P, Collado M, Barragan E, et al. Profile of polymorphisms 
of drug-metabolising enzymes and the risk of therapy-related 
leukaemia. Br J Haematol 2007;136:590-6. 
20. Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ. 
Therapy related acute myeloid leukemia in breast cancer survi-
vors, a population-based study. Breast Cancer Res Treat 2009;118: 
593-8. 
21. Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and 
myelodysplastic syndrome in trials of adjuvant epirubicin for ear-
ly breast cancer: correlation with doses of epirubicin and cyclo-
phosphamide. J Clin Oncol 2005;23:4179-91. 
22. Kaplan HG, Malmgren JA, Atwood M. Leukemia incidence fol-
lowing primary breast carcinoma treatment. Cancer 2004;101: 
1529-36. 
23. Park DJ, Koeffler HP. Therapy-related myelodysplastic synd-
romes. Semin Hematol 1996;33:256-73. 
24. Pagano L, Pulsoni A, Tosti ME, et al. Acute lymphoblastic leukae-
mia occurring as second malignancy: report of the GIMEMA ar-
chive of adult acute leukaemia. Gruppo Italiano Malattie Emato-
logiche Maligne dell'Adulto. Br J Haematol 1999;106:1037-40. 
25. Cole M, Strair R. Acute myelogenous leukemia and myelodys-
plasia secondary to breast cancer treatment: case studies and liter-
ature review. Am J Med Sci 2010;339:36-40. 